{
    "xml": "<topic id=\"PHP4484\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/raloxifene-hydrochloride\" basename=\"raloxifene-hydrochloride\" title=\"RALOXIFENE HYDROCHLORIDE\">\n<title>RALOXIFENE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_864\" namespace=\"/interactions/list-of-drug-interactions/raloxifene\">Raloxifene</xref>\n</p>\n<data name=\"vtmid\">419530003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_737537666\" title=\"Selective oestrogen receptor modulators\">Selective oestrogen receptor modulators</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48770\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment and prevention of postmenopausal osteoporosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>60&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48812\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Cholestasis</ph>; <ph outputclass=\"contraindication\">endometrial cancer</ph>; <ph outputclass=\"contraindication\">history of venous thromboembolism</ph>; <ph outputclass=\"contraindication\">undiagnosed uterine bleeding</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48829\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">breast cancer (manufacturer advises avoid during treatment for breast cancer)</ph>; <ph outputclass=\"caution\">history of oestrogen-induced hypertriglyceridaemia (monitor serum triglycerides)</ph>; <ph outputclass=\"caution\">risk factors for stroke</ph>; <ph outputclass=\"caution\">risk factors for venous thromboembolism (discontinue if prolonged immobilisation)</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP48758\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (raloxifene).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48718\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hot flushes</ph>; <ph outputclass=\"sideEffect\">influenza-like symptoms</ph>; <ph outputclass=\"sideEffect\">leg cramps</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Thrombophlebitis</ph>; <ph outputclass=\"sideEffect\">venous thromboembolism</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arterial thromboembolism</ph>; <ph outputclass=\"sideEffect\">breast discomfort</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">migraine</ph>; <ph outputclass=\"sideEffect\">rashes</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48780\" outputclass=\"hepaticImpairment\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48738\" outputclass=\"renalImpairment\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48675\" outputclass=\"nationalFunding\" rev=\"1.34\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA160</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p>\r\n<p>\r\n<b>Raloxifene</b> is <b>not</b> recommended as a treatment option in postmenopausal women for primary prevention of osteoporotic fractures.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA160\">www.nice.org.uk/TA160</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA161</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p>\r\n<p>This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.</p>\r\n<p>\r\n<b>Raloxifene</b> is recommended as an alternative treatment option for women:</p>\r\n<ul>\r\n<li>in whom alendronate and risedronate are contra-indicated or not tolerated <b>and</b>\r\n</li>\r\n<li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance (available at www.nice.org.uk/TA161).</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA161\">www.nice.org.uk/TA161</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4484-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/raloxifene-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75497\" title=\"Tablet\" namespace=\"/drugs/raloxifene-hydrochloride/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78314\" namespace=\"/treatment-summaries/bone-metabolism\" title=\"Bone metabolism\" count=\"1\" rel=\"backlink\">Bone metabolism</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78400\" namespace=\"/treatment-summaries/sex-hormones\" title=\"Sex hormones\" count=\"3\" rel=\"backlink\">Sex hormones</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_864\" namespace=\"/interactions/list-of-drug-interactions/raloxifene\" title=\"Raloxifene\" count=\"1\" rel=\"link\">Raloxifene</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75497\" namespace=\"/drugs/raloxifene-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4484",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/raloxifene-hydrochloride",
    "basename": "raloxifene-hydrochloride",
    "title": "RALOXIFENE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_864",
            "label": "Raloxifene"
        }
    ],
    "vtmid": "419530003",
    "drugClassification": [
        "Selective oestrogen receptor modulators"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment and prevention of postmenopausal osteoporosis",
                        "html": "Treatment and prevention of postmenopausal osteoporosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "60 mg once daily.",
                        "html": "<p>60&#8239;mg once daily.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Cholestasis",
                "html": "Cholestasis"
            },
            {
                "type": "contraindications",
                "textContent": "endometrial cancer",
                "html": "endometrial cancer"
            },
            {
                "type": "contraindications",
                "textContent": "history of venous thromboembolism",
                "html": "history of venous thromboembolism"
            },
            {
                "type": "contraindications",
                "textContent": "undiagnosed uterine bleeding",
                "html": "undiagnosed uterine bleeding"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "breast cancer (manufacturer advises avoid during treatment for breast cancer)",
                "html": "breast cancer (manufacturer advises avoid during treatment for breast cancer)"
            },
            {
                "type": "cautions",
                "textContent": "history of oestrogen-induced hypertriglyceridaemia (monitor serum triglycerides)",
                "html": "history of oestrogen-induced hypertriglyceridaemia (monitor serum triglycerides)"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for stroke",
                "html": "risk factors for stroke"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for venous thromboembolism (discontinue if prolonged immobilisation)",
                "html": "risk factors for venous thromboembolism (discontinue if prolonged immobilisation)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (raloxifene).",
                "html": "<p>Appendix 1 (raloxifene).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Hot flushes",
                        "html": "Hot flushes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "influenza-like symptoms",
                        "html": "influenza-like symptoms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "leg cramps",
                        "html": "leg cramps",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Thrombophlebitis",
                        "html": "Thrombophlebitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "venous thromboembolism",
                        "html": "venous thromboembolism",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Arterial thromboembolism",
                        "html": "Arterial thromboembolism",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "breast discomfort",
                        "html": "breast discomfort",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "migraine",
                        "html": "migraine",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rashes",
                        "html": "rashes",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in mild to moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA160",
                        "label": "www.nice.org.uk/TA160"
                    }
                ],
                "fundingIdentifier": "NICE TA160",
                "textContent": "Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) Raloxifene is not recommended as a treatment option in postmenopausal women for primary prevention of osteoporotic fractures.\n\nwww.nice.org.uk/TA160",
                "html": "<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p> <p> <b>Raloxifene</b> is <b>not</b> recommended as a treatment option in postmenopausal women for primary prevention of osteoporotic fractures.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA160\">www.nice.org.uk/TA160</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA161",
                        "label": "www.nice.org.uk/TA161"
                    }
                ],
                "fundingIdentifier": "NICE TA161",
                "textContent": "Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture. Raloxifene is recommended as an alternative treatment option for women: in whom alendronate and risedronate are contra-indicated or not tolerated and who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance (available at www.nice.org.uk/TA161).\n\nwww.nice.org.uk/TA161",
                "html": "<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p> <p>This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.</p> <p> <b>Raloxifene</b> is recommended as an alternative treatment option for women:</p> <ul> <li>in whom alendronate and risedronate are contra-indicated or not tolerated <b>and</b> </li> <li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance (available at www.nice.org.uk/TA161).</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA161\">www.nice.org.uk/TA161</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75497",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78314",
                "label": "Bone metabolism",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78400",
                "label": "Sex hormones",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_864",
                "label": "Raloxifene",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75497",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}